PURPOSE: The aim of this study was to investigate the potential of the synergetic triple therapeutic combination encompassing bismuth oxide nanoparticles (BiONPs), cisplatin (Cis), and high dose rate (HDR) brachytherapy with Ir-192 source in breast cancer and normal fibroblast cell line. METHODS: In vitro models of breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblast cell line (NIH/3T3) were employed. Cellular localization and cytotoxicity studies were conducted prior to inspection on the radiosensitization effects and generation of reactive oxygen species (ROS) on three proposed radiosensitizers: BiONPs, Cis, and BiONPs-Cis combination (BC). The optimal, non-cytotoxic concentration of BiONPs (0.5 mM) and the 25% inhibitory concentration of Cis (1.30 µM) were applied. The radiosensitization effects were evaluated by using a 0.38 MeV Iridium-192 HDR brachytherapy source over a prescribed dose range of 0 Gy to 4 Gy. RESULTS: The cellular localization of BiONPs was visualized by light microscopy and accumulation of the BiONPs within the vicinity of the nuclear membrane was observed. Quantification of the sensitization enhancement ratio extrapolated from the survival curves indicates radiosensitization effects for MCF-7 and MDA-MB-231 when treated with BiONPs, Cis, and BC. However, NIH/3T3 cells exhibited contradictive behavior as it only reacted towards the BC combination. Nonetheless, the MCF-7 cell line loaded with BC shows the highest SER of 4.29. ROS production analysis, on the other hand, shows that Cis and BC radiosensitizers generated the highest free radicals in comparison to BiONPs alone. CONCLUSION: A BiONPs-Cis combination was unveiled as a novel approach that offers promising radiosensitization enhancement that will increase the efficiency of tumor control while preserving the normal tissue at a reduced dose. This data is the first precedent to prove the synergetic implication of BiONPs, Cis, and HDR brachytherapy that will be beneficial for future chemoradiotherapy strategies in cancer care.
PURPOSE: The aim of this study was to investigate the potential of the synergetic triple therapeutic combination encompassing bismuth oxide nanoparticles (BiONPs), cisplatin (Cis), and high dose rate (HDR) brachytherapy with Ir-192 source in breast cancer and normal fibroblast cell line. METHODS: In vitro models of breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblast cell line (NIH/3T3) were employed. Cellular localization and cytotoxicity studies were conducted prior to inspection on the radiosensitization effects and generation of reactive oxygen species (ROS) on three proposed radiosensitizers: BiONPs, Cis, and BiONPs-Cis combination (BC). The optimal, non-cytotoxic concentration of BiONPs (0.5 mM) and the 25% inhibitory concentration of Cis (1.30 µM) were applied. The radiosensitization effects were evaluated by using a 0.38 MeV Iridium-192 HDR brachytherapy source over a prescribed dose range of 0 Gy to 4 Gy. RESULTS: The cellular localization of BiONPs was visualized by light microscopy and accumulation of the BiONPs within the vicinity of the nuclear membrane was observed. Quantification of the sensitization enhancement ratio extrapolated from the survival curves indicates radiosensitization effects for MCF-7 and MDA-MB-231 when treated with BiONPs, Cis, and BC. However, NIH/3T3 cells exhibited contradictive behavior as it only reacted towards the BC combination. Nonetheless, the MCF-7 cell line loaded with BC shows the highest SER of 4.29. ROS production analysis, on the other hand, shows that Cis and BC radiosensitizers generated the highest free radicals in comparison to BiONPs alone. CONCLUSION: A BiONPs-Cis combination was unveiled as a novel approach that offers promising radiosensitization enhancement that will increase the efficiency of tumor control while preserving the normal tissue at a reduced dose. This data is the first precedent to prove the synergetic implication of BiONPs, Cis, and HDR brachytherapy that will be beneficial for future chemoradiotherapy strategies in cancer care.
Authors: Seema Gupta; Tulay Koru-Sengul; Susanne M Arnold; Gayathri R Devi; Mohammed Mohiuddin; Mansoor M Ahmed Journal: Mol Cancer Ther Date: 2011-01-07 Impact factor: 6.261
Authors: Tae-Hyun Kim; Meeju Kim; Hyung-Seok Park; Ueon Sang Shin; Myoung-Seon Gong; Hae-Won Kim Journal: J Biomed Mater Res A Date: 2012-02-05 Impact factor: 4.396
Authors: Noor Nabilah Talik Sisin; Khairunisak Abdul Razak; Safri Zainal Abidin; Nor Fazila Che Mat; Reduan Abdullah; Raizulnasuha Ab Rashid; Muhammad Afiq Khairil Anuar; Wan Nordiana Rahman Journal: Int J Nanomedicine Date: 2020-10-12
Authors: Noor Nabilah Talik Sisin; Nor Fazila Che Mat; Raizulnasuha Ab Rashid; Norhayati Dollah; Khairunisak Abdul Razak; Moshi Geso; Merfat Algethami; Wan Nordiana Rahman Journal: Int J Nanomedicine Date: 2022-09-02
Authors: Maria A Kolyvanova; Alexandr V Belousov; Grigorii A Krusanov; Alexandra K Isagulieva; Kirill V Morozov; Maria E Kartseva; Magomet H Salpagarov; Pavel V Krivoshapkin; Olga V Dement'eva; Victor M Rudoy; Vladimir N Morozov Journal: Int J Mol Sci Date: 2021-06-02 Impact factor: 5.923